Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BH4 dosing timing study in phenylketonuria
NL-OMON25048Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sapropterin in phenylketonuria (PKU) (3 arms), sponsored by University Medical Center Groningen. Primary endpoint: Blood phenylalanine variation. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
sapropterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NL-OMON25048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25048.